Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NVS

Novartis AG ADR

Apr 25 • 09:55AM ET

98.55

Dollar change +0.20
Percentage change 0.20	%

Healthcare • Drug Manufacturers - General • Switzerland • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	13.38	EPS (ttm)	7.37	Insider Own	0.00%	Shs Outstand	2.04B	Perf Week	6.46%
Market Cap	192.81B	Forward P/E	12.57	EPS next Y	7.84	Insider Trans	-	Shs Float	1.96B	Perf Month	3.44%
Income	15.24B	PEG	2.00	EPS next Q	1.82	Inst Own	7.27%	Short Float	0.19%	Perf Quarter	-7.89%
Sales	48.66B	P/S	3.96	EPS this Y	10.89%	Inst Trans	-9.16%	Short Ratio	2.39	Perf Half Y	3.84%
Book/sh	19.44	P/B	5.07	EPS next Y	9.24%	ROA	8.86%	Short Interest	3.81M	Perf Year	0.10%
Cash/sh	4.95	P/C	19.89	EPS next 5Y	6.67%	ROE	19.96%	52W Range	88.86 - 108.78	Perf YTD	-2.40%
Dividend Est.	3.67 (3.72%)	P/FCF	15.16	EPS past 5Y	5.63%	ROI	26.11%	52W High	-9.40%	Beta	0.54
Dividend TTM	3.74 (3.79%)	Quick Ratio	0.71	Sales past 5Y	0.78%	Gross Margin	72.13%	52W Low	10.90%	ATR (14)	1.48
Dividend Ex-Date	Mar 07, 2024	Current Ratio	0.90	EPS Y/Y TTM	125.94%	Oper. Margin	26.06%	RSI (14)	60.40	Volatility	1.44% 1.10%
Employees	76057	Debt/Eq	0.69	Sales Y/Y TTM	-4.53%	Profit Margin	31.33%	Recom	2.58	Target Price	109.86
Option/Short	Yes / Yes	LT Debt/Eq	0.47	EPS Q/Q	20.88%	Payout	44.73%	Rel Volume	1.28	Prev Close	98.35
Sales Surprise	3.40%	EPS Surprise	7.29%	Sales Q/Q	-8.68%	Earnings	Apr 23 BMO	Avg Volume	1.59M	Price	98.55
SMA20	3.64%	SMA50	0.60%	SMA200	0.44%	Trades		Volume	225,699	Change	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform
Sep-14-22	Downgrade	Berenberg	Buy → Hold
May-09-22	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-22	Resumed	Citigroup	Buy
Dec-14-21	Downgrade	Redburn	Buy → Neutral
Dec-06-21	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-03-21	Downgrade	Bryan Garnier	Buy → Neutral
Sep-20-21	Downgrade	Deutsche Bank	Hold → Sell
Mar-22-21	Initiated	Bernstein	Mkt Perform
Mar-10-21	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Today 08:30AM	Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market (Investor's Business Daily)
Apr-24-24 11:42AM	Novartis bags paediatric FDA label expansion for Lutathera (Pharmaceutical Technology)
10:54AM	Novartis Says New Malaria Drug Formulation Safe and Effective for Babies (MT Newswires)
10:30AM	Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 06:25PM	Why Novartis Stock Topped the Market on Tuesday (Motley Fool)
05:05PM	Loading…
05:05PM	FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors (Benzinga)
04:01PM	How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint (Investor's Business Daily)
03:18PM	Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children (MT Newswires)
02:38PM	Novartis CEO: Here's why we boosted our full-year guidance (CNBC TV)
01:54PM	Top Stock Movers Now: General Motors, Kimberly-Clark, PepsiCo, and More (Investopedia)
01:42PM	Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors (GlobeNewswire)
12:53PM	NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
12:34PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:24PM	Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock (MT Newswires)
12:16PM	Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb (Investopedia)
12:15PM	Loading…
12:15PM	Analyst Report: Novartis AG (Morningstar Research)
12:07PM	Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024 (Associated Press Finance)
11:32AM	Novartis Stock Jumps After Beating Expectations, Raising Guidance (The Wall Street Journal)
11:15AM	Novartis Ag (NVS) Q1 2024 Earnings Call Transcript (Motley Fool)
10:51AM	Novartis raises full-year guidance on Q1 beat, drug sales (Yahoo Finance Video)
09:30AM	Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics (Zacks)
09:00AM	Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised (Zacks)
08:59AM	Stocks to Watch Tuesday: GM, Spotify, UPS, Tesla (The Wall Street Journal)
08:52AM	Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise (Investor's Business Daily)
07:45AM	Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated (MT Newswires)
07:29AM	Stocks to Watch Tuesday: UPS, Spotify, GM, Tesla (The Wall Street Journal)
05:15AM	Stocks to Watch Tuesday: Tesla, Tapestry, Cadence Design Systems (The Wall Street Journal)
05:02AM	Novartis: Q1 Earnings Snapshot (Associated Press Finance)
04:58AM	UPDATE 1-Healthcare, tech stocks boost STOXX 600 to one-week high (Reuters)
04:31AM	Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up (RTT News)
04:08AM	Loading…
04:08AM	Novartis Raises Guidance on Profit, Sales Growth (The Wall Street Journal)
03:01AM	Techs boost STOXX to one-week high; euro zone data on tap (Reuters)
01:18AM	UPDATE 4-Novartis raises guidance after beating Q1 expectations (Reuters)
01:00AM	Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised (GlobeNewswire)
Apr-22-24 06:08PM	25 Richest Billionaires in Healthcare Industry (Insider Monkey)
Apr-19-24 10:10AM	Novartis (NVS) to Report Q1 Earnings: What to Expect? (Zacks)
Apr-18-24 06:33PM	US FDA mandates label updates on CAR-T cancer therapies (Reuters)
09:15AM	Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-17-24 09:30AM	2 High-Yield Dividend Stocks to Buy and Hold for 10 Years (Motley Fool)
01:15AM	Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis (GlobeNewswire)
Apr-16-24 09:06AM	Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug (Zacks)
Apr-15-24 02:00PM	New Novartis Fabhalta (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) (PR Newswire)
04:46AM	Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining. (Yahoo Finance)
Apr-12-24 01:55PM	Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate (Zacks)
08:53AM	NICE recommends Novartis' CAR-T therapy for leukaemia (Pharmaceutical Business Review)
06:26AM	Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing (FierceBiotech.com)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
11:27AM	Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials (Quartz)
09:45AM	Novartis (NVS) to Undertake Job Cuts in Development Department (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
08:06AM	Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader (FierceBiotech.com)
07:40AM	UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion (Reuters)
07:17AM	Novartis licenses Arvinas' cancer drug for up to $1 billion (Reuters)
07:00AM	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer (GlobeNewswire)
04:39AM	UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys (Reuters)
04:20AM	Novartis tender offer for MorphoSys AG commences (GlobeNewswire)
Apr-10-24 10:12AM	Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts (InvestorPlace)
08:11AM	Novartis pauses some trials of cancer drug Kisqali to fix manufacturing (BioPharma Dive)
08:11AM	Novartis pauses enrollment in some Kisqali trials to fix manufacturing (BioPharma Dive)
Apr-09-24 10:15AM	Novartis to cut 680 jobs in product development (Reuters)
Apr-06-24 04:16PM	New Novartis data show early addition of twice-yearly* Leqvio (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting (PR Newswire)
Apr-05-24 06:00PM	Novartis (NVS) Stock Sinks As Market Gains: Here's Why (Zacks)
Apr-04-24 03:42PM	Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study (Investopedia)
Apr-03-24 08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
Apr-02-24 06:15PM	Novartis (NVS) Declines More Than Market: Some Information for Investors (Zacks)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-31-24 04:34PM	25 Countries with Highest Malaria Death Rates (Insider Monkey)
Mar-30-24 03:52PM	11 Oversold Blue Chip Stocks to Buy Right Now (Insider Monkey)
Mar-29-24 05:02PM	15 Biggest Swiss Companies (Insider Monkey)
Mar-28-24 09:00AM	Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know (Zacks)
Mar-27-24 06:00PM	Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
Mar-26-24 01:06PM	Harnessing AI for Drug Discovery: Top 3 Stocks to Watch (InvestorPlace)
07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
06:18AM	25 Countries with the Highest Death Rate From Malnutrition (Insider Monkey)
Mar-25-24 06:15PM	Novartis (NVS) Declines More Than Market: Some Information for Investors (Zacks)
12:58PM	30 Countries with Highest Proportion of Older Adults (Insider Monkey)
07:26AM	EMA CHMP recommends marketing authorisation for Novartis' PNH treatment (Pharmaceutical Business Review)
Mar-24-24 10:40AM	5 Most Undervalued Large-Cap Stocks To Buy According To Analysts (Insider Monkey)
08:15AM	1 Magnificent Dividend Stock to Buy and Hold (Motley Fool)
Mar-22-24 07:22AM	Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
Mar-19-24 06:00PM	Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
Mar-18-24 06:15PM	Novartis (NVS) Stock Dips While Market Gains: Key Facts (Zacks)
01:28PM	US appeals court revives Regeneron's antitrust lawsuit against Novartis (Reuters)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
09:00AM	Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock (Zacks)
08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-13-24 09:02AM	Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront (FierceBiotech.com)
07:08AM	IFM, an unorthodox biotech startup, scores third buyout with Novartis deal (BioPharma Dive)
Mar-12-24 06:00PM	Novartis (NVS) Stock Dips While Market Gains: Key Facts (Zacks)
Mar-11-24 06:15PM	Novartis (NVS) Advances While Market Declines: Some Information for Investors (Zacks)
12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-10-24 06:35AM	3 Dividend Stocks to Buy Hand Over Fist in March (Motley Fool)
Mar-06-24 05:01AM	Novartis AG's Dividend Analysis (GuruFocus.com)
Mar-05-24 06:00PM	Novartis (NVS) Gains As Market Dips: What You Should Know (Zacks)
09:22AM	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
02:56AM	13 Best Pharma Dividend Stocks To Buy in 2024 (Insider Monkey)
Mar-04-24 01:15AM	Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA (GlobeNewswire)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your FINVIZ experience